Bram De Wilde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7282607/publications.pdf

Version: 2024-02-01

36 papers 2,787 citations

16 h-index 414414 32 g-index

41 all docs

41 docs citations

times ranked

41

5786 citing authors

#	Article	IF	CITATIONS
1	Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. Critical Reviews in Oncology/Hematology, 2022, 169, 103564.	4.4	12
2	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. European Journal of Cancer, 2022, 160, 12-23.	2.8	16
3	Cellular senescence in neuroblastoma. British Journal of Cancer, 2022, 126, 1529-1538.	6.4	5
4	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion Neuro-Oncology, 2022, 24, i61-i62.	1.2	0
5	RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Science Advances, 2022, 8 , .	10.3	15
6	Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome. Epigenetics, 2021, 16, 797-807.	2.7	21
7	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. Epigenetics, 2021, 16, 196-208.	2.7	23
8	Purpura fulminans: How varicella zoster can result in acquired protein S deficiency. International Journal of Laboratory Hematology, 2021, 43, 146-147.	1.3	0
9	Factors Influencing Change in MCV and Age at Transplantation in the Belgian Sickle Cell Disease Registry. Blood, 2021, 138, 4171-4171.	1.4	O
10	From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 1286.	2.5	2
11	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics, 2020, 179, 191-202.	2.7	55
12	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
13	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
14	The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. Scientific Reports, 2020, 10, 218.	3.3	20
15	Pinpointing a potential role for <i>CLEC12B</i> in cancer predisposition through familial exome sequencing. Pediatric Blood and Cancer, 2019, 66, e27513.	1.5	3
16	Hypotonia and delayed motor development as an early presentation of Lowe syndrome: case report and literature review. Acta Clinica Belgica, 2019, 74, 460-464.	1.2	4
17	ALK positively regulates MYCN activity through repression of HBP1 expression. Oncogene, 2019, 38, 2690-2705.	5.9	17
18	Severe anaphylactic reaction following anti-thymocyte globulin administration in a pediatric stem cell transplantation patient. Journal of Oncology Pharmacy Practice, 2018, 24, 232-234.	0.9	2

#	Article	IF	Citations
19	A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170.	12.6	213
20	The mutational landscape of <i>MYCN</i> , <i>Lin28b</i> and <i>ALKF1174L</i> driven murine neuroblastoma mimics human disease. Oncotarget, 2018, 9, 8334-8349.	1.8	6
21	Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients. Clinical Cancer Research, 2017, 23, 6305-6314.	7.0	113
22	High-throughput PCR assay design for targeted resequencing using primerXL. BMC Bioinformatics, 2017, 18, 400.	2.6	13
23	Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait. Epigenetics, 2016, 11, 761-771.	2.7	24
24	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget, 2016, 7, 1960-1972.	1.8	26
25	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526, 700-704.	27.8	478
26	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. PLoS ONE, 2014, 9, e114696.	2.5	15
27	Emergence of New <i>ALK</i> Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	1.6	176
28	Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatric Blood and Cancer, 2014, 61, 1867-1870.	1.5	5
29	Target enrichment using parallel nanoliter quantitative PCR amplification. BMC Genomics, 2014, 15, 184.	2.8	17
30	Complex genetics of radial ray deficiencies: screening of a cohort of 54 patients. Genetics in Medicine, 2013, 15, 195-202.	2.4	15
31	Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. Science Translational Medicine, 2012, 4, 141ra91.	12.4	147
32	Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis. Genetics in Medicine, 2012, 14, 576-585.	2.4	39
33	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
34	Cancer Gene Prioritization for Targeted Resequencing Using FitSNP Scores. PLoS ONE, 2012, 7, e31333.	2.5	2
35	Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics. PLoS ONE, 2011, 6, e25531.	2.5	40
36	Chromosome 3p Microsatellite Allelotyping in Neuroblastoma: A Report on the Technical Hurdles. Cancer Investigation, 2009, 27, 857-868.	1.3	0